| Report ID | 278682 |
| Drug Identification Number | 02244513 |
| Brand name | TEVA-GABAPENTIN |
| Common or Proper name | GABAPENTIN 100MG CAPSULES |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | GABAPENTIN |
| Strength(s) | 100MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 500 |
| ATC code | N02BF |
| ATC description | |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2026-02-23 |
| Estimated end date | 2026-06-01 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2026-02-26 |
| Company comments | Issue at MFG'er Product is being allocated. Date shown is next allocation date. Actual recovery TBD. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2026-02-26 | French | Compare |
| v6 | 2026-02-26 | English | Compare |
| v5 | 2026-02-26 | French | Compare |
| v4 | 2026-02-26 | English | Compare |
| v3 | 2026-02-23 | French | Compare |
| v2 | 2026-02-23 | English | Compare |
| v1 | 2026-02-23 | English | Compare |
Showing 1 to 7 of 7